Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003246 | 1.00 | SPHK1 (0.38) | SPHK1CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL1003245 | 1.00 | SPHK1 (0.38) | SPHK1CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL1001360 | 0.85 | TLR4 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL1001362 | 0.85 | TLR4 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12371065 | 0.79 | SPHK1 (0.39) | SPHK1ALDH1A1MAPTSPHK2MEN1 | |
| SCHEMBL10552463 | 0.79 | KMT2A (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12926639 | 0.78 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL12926593 | 0.77 | KMT2A (0.33) | KMT2A | |
| SCHEMBL13023796 | 0.76 | CYP2C9 (0.43) | SPHK1CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12926602 | 0.75 | KMT2A (0.32) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875327-B2 | nematic phase consisting of a lactone ring of pyranone, a cyclohexylene or 1,4-phenylene ring, or replaced by one or more fluorine; controlling temperature, optical and dielectric anisotropy, photostability, heat resistance | CHISSO CORPORATION (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20100038588-A1 | Liquid Crystal Compound Having Lactone Ring, Liquid Crystal Composition, And Liquid Crystal Display Device | CHISSO CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7618688-B2 | Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1785467-B1 | Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device | CHISSO CORP (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20070108410-A1 | Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION | 2007-05-17 | — | — | US | disclosed |
| EP-1785467-A1 | Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100038588-A1 | Liquid Crystal Compound Having Lactone Ring, Liquid Crystal Composition, And Liquid Crystal Display Device | TCF7L2, TCF7, CA7 | SPHK1 3162/4885CYP2C9 1707/4885ALDH1A1 570/4885 |
| US-20070108410-A1 | Liquid crystal compound having lactone ring, liquid crystal composition, and liquid crystal display device | TCF7L2, TCF7, CA7 | SPHK1 3218/4885CYP2C9 1738/4885ALDH1A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.